Evidence map›Paper›PMID 33368269›Full record

ReviewImmunology2021

Macrophage reprogramming for therapy.

Valentina M T Bart, Robert J Pickering, Philip R Taylor, Natacha Ipseiz

Abstract readReview
In one paragraph

Review in Immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Valentina M T BartSystems Immunity Research Institute, Cardiff University, Cardiff, UK.ORCID 0000-0001-8650-5621
Robert J PickeringImmunology Network, Adaptive Immunity Research Unit, GlaxoSmithKline, Stevenage, UK.ORCID 0000-0003-3332-9868
Philip R TaylorSystems Immunity Research Institute, Cardiff University, Cardiff, UK.ORCID 0000-0003-0163-1421
Natacha IpseizSystems Immunity Research Institute, Cardiff University, Cardiff, UK.ORCID 0000-0001-5008-8889

Funding

Medical Research CouncilWellcome TrustWellcome Trust 07964/Z/15/Z
6 · The paper itself

Abstract

Dysfunction of the immune system underlies a plethora of human diseases, requiring the development of immunomodulatory therapeutic intervention. To date, most strategies employed have been focusing on the modification of T lymphocytes, and although remarkable improvement has been obtained, results often fall short of the intended outcome. Recent cutting-edge technologies have highlighted macrophages as potential targets for disease control. Macrophages play central roles in development, homeostasis and host defence, and their dysfunction and dysregulation have been implicated in the onset and pathogenesis of multiple disorders including cancer, neurodegeneration, autoimmunity and metabolic diseases. Recent advancements have led to a greater understanding of macrophage origin, diversity and function, in both health and disease. Over the last few years, a variety of strategies targeting macrophages have been developed and these open new therapeutic opportunities. Here, we review the progress in macrophage reprogramming in various disorders and discuss the potential implications and challenges for macrophage-targeted approaches in human disease.

Indexed as

AnimalsAutoimmune DiseasesCell DifferentiationCellular ReprogrammingHumansImmunotherapyMacrophagesMetabolic DiseasesNeoplasmsNeurodegenerative Diseasesmacrophagespolarizationreprogramming

Identifiers

PMID33368269
PMCPMC8114216

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.